In the AML group, the most frequently affected pathways and genes included the following: epigenetic regulators (e.g., DNMT3A and IDH1/IDH2), observed in 91% of cases; the FLT3-RAS pathway (e.g., FLT3 ITD) in 65% of cases; transcription factors (e.g., RUNX1) in 45% of cases; spliceosome genes (e.g., U2AF1 and SRSF2) in 37% of cases; and cohesion genes (e.g., STAG2) in 20% of cases. The gene discussed is RUNX1; the disease is acute myeloid leukemia.